Lantern Pharma Inc.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A INFORMATION

PROXY STATEMENT PURSUANT TO SECTION 14(A) OF

THE SECURITIES EXCHANGE ACT OF 1934

Check the appropriate box:

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

October 19, 2026

Dear Stockholder:

You are cordially invited to attend the 2026 Annual Meeting of Stockholders (which we refer to as the “Annual Meeting”) of Lantern Pharma Inc., a Delaware corporation (which we refer to as “Lantern,” “we,” “us,” “our,” or the “Company”), to be held at 11:00 a.m. Eastern time, on Tuesday, December 1, 2026.

This year’s Annual Meeting will be conducted via live audio webcast and online stockholder tools. Stockholders will be able to attend and listen to the Annual Meeting live, submit questions and vote their shares electronically at the Annual Meeting from virtually any location around the world.

At the Annual Meeting, you will be asked to consider and vote upon the following proposals to: (1) elect six (6) directors to serve as members of the Board of Directors of the Company until the next annual meeting; (2) adopt an amendment to the Company’s Certificate of Incorporation to increase the Company’s authorized common stock to 50 million shares; (3) approve an amendment to the Second Amended and Restated 2018 Lantern Pharma Inc. Equity Incentive Plan, as amended, to increase the number of shares of the Company’s common stock available for issuance under the plan by an additional 250,000 shares; (4) approval of the issuance of up to 3,669,725 shares of the Company’s common stock issuable upon exercise of purchase warrants sold by us to an institutional investor; (5) ratify the appointment of EisnerAmper LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026; (6) approve, on an advisory basis, the compensation of our named executive officers described in the accompanying Proxy Statement; and (7) indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the named executive officers. The accompanying Proxy Statement describes these matters in more detail. We urge you to read this information carefully.

The Board of Directors recommends a vote: FOR each of the six (6) nominees for director named in the Proxy Statement; FOR the adoption of an amendment to the Company’s Certificate of Incorporation to increase the Company’s authorized common stock; FOR the approval of the amendment to the Second Amended and Restated Lantern Pharma Inc. 2018 Equity Incentive Plan, as amended, to increase the number of shares of the Company’s common stock available for issuance under the plan; FOR approval of the issuance of shares of the Company’s common stock issuable upon exercise of purchase warrants sold by us to an institutional investor; FOR the ratification of the appointment of EisnerAmper LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026; FOR the approval, on an advisory basis, of the compensation of our named executive officers as described in the Proxy Statement; and FOR the indication, on an advisory basis, of “one year” as the preferred frequency of stockholder advisory votes on the compensation of the named executive officers..

Whether or not you plan to attend the Annual Meeting in person, and regardless of the number of shares of Lantern that you own, it is important that your shares be represented and voted at the Annual Meeting. Therefore, I urge you to vote your shares of common stock via the Internet or by promptly marking, dating, signing, and returning a proxy card in the envelope provided. Voting over the Internet, or by written proxy, will ensure that your shares are represented at the Annual Meeting.

On behalf of the Board of Directors of Lantern, we thank you for your participation.

Sincerely,

/s/ Donald J. Keyser

Donald J. Keyser,

Chairman of the Board of Directors

1920 McKinney Avenue, 7 th Floor

Dallas, Texas 75201

NOTICE OF 2026 ANNUAL MEETING OF STOCKHOLDERS

TO BE HELD ON December 1, 2026

The 2026 Annual Meeting of Stockholders (which we refer to as the “Annual Meeting”) of Lantern Pharma Inc., a Delaware corporation (which we refer to as “Lantern,” “we,” “us,” “our,” or the “Company”), will be held on Tuesday, December 1, 2026 at 11:00 a.m. Eastern time. This year’s meeting is a virtual stockholder meeting conducted exclusively via a live audio webcast atwww.virtualshareholdermeeting.com/LTRN2026. Stockholders will be able to attend and listen to the Annual Meeting live, submit questions and vote their shares electronically at the Annual Meeting from virtually any location around the world. In order to attend and vote at the Annual Meeting, please follow the instructions in the section titled “Voting at the Meeting” on page 3. We will consider and act on the following items of business at the Annual Meeting:

We intend to commence mailing the Annual Report, Notice of Meeting, Proxy Statement and Proxy Card on or about October 21, 2026 to all stockholders entitled to vote at the Annual Meeting.

The accompanying Proxy Statement describes each of these items of business in detail. Only stockholders of record at the close of business on October 5, 2026 are entitled to receive notice of, attend and vote at the Annual Meeting or any continuation, postponement or adjournment thereof.

All stockholders as of the record date, or who hold a valid proxy, are cordially invited to attend the Annual Meeting via the Internet atwww.virtualshareholdermeeting.com/LTRN2026. To ensure your representation at the Annual Meeting, you are urged to vote your shares of common stock via the Internet or by promptly marking, dating, signing, and returning the proxy card in the envelope provided. Voting instructions are provided on the proxy card and included in the accompanying Proxy Statement. Any stockholder attending the Annual Meeting may vote at the meeting even if he or she previously submitted a proxy. If your shares of common stock are held by a bank, broker or other agent, please follow the instructions from your bank, broker or other agent to have your shares voted.

/s/ Donald J. Keyser

Donald J. Keyser,

Chairman of the Board of Directors

Dallas, Texas

October 19, 2026

TABLE OF CONTENTS

i

1920 McKinney Avenue, 7 th Floor

Dallas, Texas 75201

PROXY STATEMENT

FOR ANNUAL MEETING OF STOCKHOLDERS

TO BE HELD ON DECEMBER 1, 2026